No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Disc Medicine, Inc. (IRON) stock was $63.58 as of Oct 6, 2026, 10:00 AM EDT, up 0.39% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -6.5% · 3-year avg +11.9%/yr · 5-year avg +10.7%/yr
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company.
Biotechnology · Watertown, MA
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-1.63
Revenue Est.
$1.88M
Last Quarter Results
EPS
$-1.54
vs Estimate
$-1.77
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1IRON | $2.44B | $63.58 | +0.39% | -6.54% | +10.70% | N/A | N/A |
| 2LQDA | $2.47B | $27.79 | +0.54% | +23.11% | +59.01% | N/A | vs IRON |
| 3RXRX | $2.48B | $4.72 | -1.23% | -12.88% | -25.86% | N/A | vs IRON |
| 4CLOV | $2.39B | $4.62 | -1.39% | +80.19% | -8.36% | N/A | vs IRON |
| 5ADMA | $2.37B | $10.23 | +1.19% | -30.91% | +54.74% | +3.85% | vs IRON |
| 6ALMR | $2.56B | $36.95 | -3.09% | N/A | N/A | N/A | vs IRON |
forward FY estimate
N/A
$0.00
vs Estimate
$1.00M
Consensus Rating
Based on 12 analysts
Average Price Target
$103.17
+62.3% upside
Low
$83.00
Current
$63.58
High
$128.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-1.74 | $-1.63 | $-1.55 | 7 |
| Quarter ending Dec 2026 | $-1.72 | $-1.67 | $-1.58 | 7 |
| Quarter ending Mar 2027 | $-1.81 | $-1.81 | $-1.81 | 2 |
| Quarter ending Jun 2027 | $-1.88 | $-1.88 | $-1.88 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-6.92 | $-6.32 | $-6.09 | 9 |
| FY 2027 | $-8.09 | $-6.85 | $-5.63 | 9 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $1.88M | $1.88M | $1.88M | 10 |
| Quarter ending Dec 2026 | $3.70M | $3.70M | $3.70M | 9 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $580000.00 | $580000.00 | $580000.00 | 9 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $1.64M | $3.16M | $5.00M | 7 |
| FY 2027 | $5.56M | $34.85M | $58.92M | 9 |
